Your browser doesn't support javascript.
loading
Premature Valvular Heart Disease in Homozygous Familial Hypercholesterolemia.
Fahed, Akl C; Shibbani, Kamel; Andary, Rabih R; Arabi, Mariam T; Habib, Robert H; Nguyen, Denis D; Haddad, Fady F; Moubarak, Elie; Nemer, Georges; Azar, Sami T; Bitar, Fadi F.
Afiliación
  • Fahed AC; Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
  • Shibbani K; Departments of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Andary RR; Departments of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Arabi MT; Departments of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Habib RH; The Society of Thoracic Surgeons, Chicago, IL, USA.
  • Nguyen DD; Department of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston, MA, USA.
  • Haddad FF; Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
  • Moubarak E; National LDL Apheresis Center, Dahr El Bacheck Government University Hospital, Dahr El-Bachek, Lebanon.
  • Nemer G; Biochemistry and Molecular Genetics, American University of Beirut Medical Center, Beirut, Lebanon.
  • Azar ST; Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
  • Bitar FF; Departments of Pediatrics and Adolescent Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Cholesterol ; 2017: 3685265, 2017.
Article en En | MEDLINE | ID: mdl-28761763
ABSTRACT
Valvular heart disease frequently occurs as a consequence of premature atherosclerosis in individuals with familial hypercholesterolemia (FH). Studies have primarily focused on aortic valve calcification in heterozygous FH, but there is paucity of data on the incidence of valvular disease in homozygous FH. We performed echocardiographic studies in 33 relatively young patients (mean age 26 years) with homozygous FH (mean LDL of 447 mg/dL, 73% on LDL apheresis) to look for subclinical valvulopathy. Twenty-one patients had evidence of valvulopathy of the aortic or mitral valves, while seven subjects showed notable mitral regurgitation. Older patients were more likely to have aortic valve calcification (>21 versus ≤21 years 59% versus 12.5%; p = 0.01) despite lower LDL levels at the time of the study (385 versus 513 mg/dL; p = 0.016). Patients with valvulopathy were older and had comparable LDL levels and a lower carotid intima-media thickness. Our data suggests that, in homozygous FH patients, valvulopathy (1) is present across a wide age spectrum and LDL levels and (2) is less likely to be influenced by lipid-lowering treatment. Echocardiographic studies that focused on aortic root thickening and stenosis and regurgitation are thus likely an effective modality for serial follow-up of subclinical valvular heart disease.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cholesterol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cholesterol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
...